Skip to main content
SpringerLink
Log in

Eculizumab

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1257 Accesses

Abstract

Eculizumab (Soliris®, Alexion) is an IgG2/4 k monoclonal antibody that binds to the C5 complement factor, thereby inhibiting the formation and activity of the terminal components of complement. The orphan drug status was designated by FDA in 2000 for the treatment of dermatomyositis, in 2001 for idiopathic membranous glomerular nephropathy, in 2003 for paroxysmal nocturnal hemoglobinuria (PNH), in 2009 for atypical hemolytic uremic syndrome (aHUS), and in 2011 for Shiga toxin-induced HUS. EMEA recognized such status in 2003 for the treatment of PNH, in 2009 for aHUS, and in 2012 for infection-associated hemolytic uremic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eculizumab (Soliris®) BLA125166 FDA Medical Review, Mar 2007

    Google Scholar 

  2. Eculizumab (Soliris®) WC500054208 EMA Summary of product characteristics. Annex I, 2012

    Google Scholar 

  3. Eculizumab (Soliris®) WC500119185 EMA Assessment Report, Sept 2011

    Google Scholar 

  4. Eculizumab (Soliris®) Product Information, Alexion 2011

    Google Scholar 

  5. Kaplan M (2002) Eculizumab (Alexion). Curr Opin Investig Drugs 3:1017–1023

    PubMed  CAS  Google Scholar 

  6. Rother RP, Rollins S, Mojcik CF et al (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256–1264

    Article  PubMed  CAS  Google Scholar 

  7. Dmytrijuk A, Robie-Suh K, Cohen MH et al (2008) FDA Report: eculizumab (Soliris®9 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13:993–1000

    Article  PubMed  CAS  Google Scholar 

  8. Zuber J, Fakhourl F, Roumenlna LT et al (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657

    Article  PubMed  CAS  Google Scholar 

  9. Zhou Y, Gong B, Lin F et al (2007) Anti-C5 antibody treatment ameliorates weakness in experimentally acquired Myasthenia Gravis. J Immunol 179:8562–8567

    PubMed  CAS  Google Scholar 

  10. Sato D, Callegaro D, Lana-Peixoto et al (2012) Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 70:59–66

    Google Scholar 

  11. Eculizumab. WC500054212 EMA Scientific Discussion, 2007

    Google Scholar 

  12. Howard J, Barohn R, Freimer M et al (2012) Randomized, double blind, placebo-controlled, crossover, multicenter, phase II study of eculizumab in patients with refractory generalized Myasthenia Gravis (gMG). In: AAN meeting: myasthenia gravis. New Orleans, April 2012, Abstract S35.004

    Google Scholar 

  13. Pittock SJ, McKeon A, Mandrekar JN et al (2012) Pilot clinical trial of eculizumab in AQP4-Ig-G-positive NMO. In: AAN meeting, Boston, Oct 2012, Abstract T1826

    Google Scholar 

  14. Stegal MD, Chedld MF, Cornell LD (2012) The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 8:670–678

    Article  Google Scholar 

  15. Smith PK, Shernan SK, Chen JC et al (2011) Effect of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CARB I and II trials. J Thorac Cardiovasc Surg 142:89–98

    Article  PubMed  CAS  Google Scholar 

  16. Testa L, Van Gaal WJ, Bhindi R et al (2008) Pexelizumb in ischemic heart disease: a systematic review and meta-analysis on 15196 patients. J Thorac Cardiovasc Surg 136:884–893

    Article  PubMed  CAS  Google Scholar 

  17. Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622–633

    Article  PubMed  CAS  Google Scholar 

  18. Herlitz LC, Bomback AS, Markowitz GS et al (2012) Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 23: doi:10.1681/ASN.2011121186

  19. Pittock SJ, McKeon A, Mandrekar JN et al (2012) Pilot clinical trial of eculizumab in AQP4-Ig-G-positive NMPO. In: Am Neurol Ass meeting Boston, MA, October, Abstract T1826

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 70 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Eculizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_18

Download citation

Publish with us

Policies and ethics

Search

Navigation